These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1807 related items for PubMed ID: 19095124

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Kulkarni GS, Lockwood G, Evans A, Toi A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE.
    Cancer; 2007 Jun 15; 109(12):2432-8. PubMed ID: 17497649
    [Abstract] [Full Text] [Related]

  • 24. Risk stratification in clinically localized prostate cancer.
    Aprikian AG.
    Can J Urol; 2002 Jun 15; 9 Suppl 1():18-20. PubMed ID: 12121590
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS, Swords K, Schultz H, Carson CC, Wallen EM.
    J Urol; 2009 Feb 15; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [Abstract] [Full Text] [Related]

  • 28. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens.
    Epstein JI.
    J Urol; 2011 Sep 15; 186(3):790-7. PubMed ID: 21788055
    [Abstract] [Full Text] [Related]

  • 29. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.
    Eur Urol; 2011 Nov 15; 60(5):1045-54. PubMed ID: 21871709
    [Abstract] [Full Text] [Related]

  • 30. Focal therapy for prostate cancer: pathologic basis.
    Mouraviev V, Madden JF.
    Curr Opin Urol; 2009 Mar 15; 19(2):161-7. PubMed ID: 19188770
    [Abstract] [Full Text] [Related]

  • 31. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.
    Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ.
    Cancer; 2007 Aug 15; 110(4):906-10. PubMed ID: 17587207
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.
    Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A.
    BJU Int; 2012 Mar 15; 109 Suppl 2():1-7. PubMed ID: 22257098
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer.
    Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V.
    Prostate; 2005 Feb 01; 62(2):140-7. PubMed ID: 15389803
    [Abstract] [Full Text] [Related]

  • 37. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.
    Dong F, Kattan MW, Steyerberg EW, Jones JS, Stephenson AJ, Schröder FH, Klein EA.
    J Urol; 2008 Jul 01; 180(1):150-4; discussion 154. PubMed ID: 18485398
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Phased array magnetic resonance imaging for staging clinically localised prostrate cancer.
    Borre M, Lundorf E, Marcussen N, Langkilde NC, Wolf H.
    Acta Oncol; 2005 Jul 01; 44(6):589-92. PubMed ID: 16294442
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 91.